Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis

NCT01612039 is registered in ClinicalTrials.gov with Telsar Pharma Inc. as lead sponsor.

NCT NCT01612039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01612039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis
Lead sponsor
Telsar Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
April 30, 2014
Enrollment
112 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis